2020
Preventing COVID-19 Collateral Damage
Shepherd J, Friedland G. Preventing COVID-19 Collateral Damage. Clinical Infectious Diseases 2020, 71: 1564-1567. PMID: 32544952, PMCID: PMC7337641, DOI: 10.1093/cid/ciaa772.Peer-Reviewed Original Research
2013
An inter-professional ‘advocacy and activism in global health’: module for the training of physician-advocates
Peluso MJ, Seavey B, Gonsalves G, Friedland G. An inter-professional ‘advocacy and activism in global health’: module for the training of physician-advocates. Global Health Promotion 2013, 20: 70-73. PMID: 23797942, DOI: 10.1177/1757975913476908.Peer-Reviewed Original ResearchConceptsUndergraduate medical educationFormal didactic teachingInter-professional approachStudents of medicineStudent participationProfessionalism curriculumDidactic teachingInterested studentsBasic skillsMedical educationMedical studentsSpecific feedbackStudentsAdvocacy projectTraining moduleHealth advocacyHealth advocatesSkillsFuture roleAdvocacyTrainingInnovative aspectRole of physiciansCurriculumTeaching
2003
Human Immunodeficiency Virus Infection Prevention: Strategies for Clinicians
Schreibman T, Friedland G. Human Immunodeficiency Virus Infection Prevention: Strategies for Clinicians. Clinical Infectious Diseases 2003, 36: 1171-1176. PMID: 12715313, DOI: 10.1086/374359.Peer-Reviewed Original ResearchConceptsHIV infectionClinical practiceHuman immunodeficiency virus (HIV) infectionImmunodeficiency virus infectionNew HIV infectionsClinical care sitesPrevention-related activitiesClinical care settingsIntegration of preventionEffective prevention programsPublic health modelFuture prevention activitiesSpecific prevention effortsHIV diseaseVirus infectionCare settingsCare sitesBehavioral counselingClinical careMedical interventionsPrevention programsInfectionPrevention effortsHealth modelPrevention activities
1998
Public Health Implications of Antiretroviral Therapy and HIV Drug Resistance
Wainberg M, Friedland G. Public Health Implications of Antiretroviral Therapy and HIV Drug Resistance. JAMA 1998, 279: 1977-1983. PMID: 9643862, DOI: 10.1001/jama.279.24.1977.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusDrug-resistant variantsDrug-resistant virusesHIV drug resistanceAntiviral therapyPublic health implicationsDrug resistanceGenital secretionsHealth implicationsPublic health importanceAntiretroviral therapyViral burdenAntiretroviral agentsPatient adherenceTreatment failureViral loadImmunodeficiency virusResistant virusesSustained reductionHealth importanceTherapyVirusChild routeBloodSecretion